Explore the Agenda
8:00 am Check In, Coffee & Light Breakfast
8:55 am Chair’s Opening Remarks
Addressing Underserved Patient Needs Through Novel Science & Emerging Therapeutic Strategies
9:00 am Panel Discussion: Bringing Cosmetic Dermatology Back into R&D & Addressing High Patient Demand Through Scientific Innovation
- Examining why conditions such as acne, female hair loss, skin aging and aesthetic restoration remain underrepresented in dermatology drug development, despite affecting millions of patients worldwide, to identify where innovation is most needed
- Exploring how advances in regenerative medicine, longevity science, muscle restoration, skin rejuvenation and hair biology are creating new opportunities beyond traditional inflammatory dermatology, to unlock the next generation of dermatology pipelines
- Debating how industry, academia and clinicians can elevate cosmetic dermatology from a procedure-driven market to a science-led therapeutic field, strengthening evidence generation, regulatory pathways and investment in high-unmet-need patient populations
9:30 am Session Reserved for CHDR
10:00 am Raising the Efficacy Bar in Hidradenitis Suppurativa: Translating Phase 1 Data for Dual OX40L/TNFα Inhibition into the Next Generation of Disease Control
- Evaluating the clinical rationale for simultaneous OX40L and TNFα inhibition to address multiple inflammatory pathways driving HS pathogenesis and disease heterogeneity
- Reviewing Phase 1 safety, tolerability and pharmacokinetic findings supporting further development and potential once-monthly dosing in patients with HS
- Exploring how bispecific antibody approaches could improve upon TNFα monotherapy to deliver more durable responses and raise the standard of care in moderate-to-severe HS
10:30 am Session Reserved for QIMA Life Sciences
10:40 am Morning Break & Refreshments
TRACK ONE: DISCOVERY & PRECLINICAL
Advancing Disease-Modifying Therapies Through Smarter Molecule Design, Translational Strategy & Development Planning
11:30 am Advancing Disease-Modifying Therapies in Epidermolysis Bullosa Simplex to Move Beyond Wound Management & Restore Structural Integrity
- Targeting the underlying keratin dysfunction driving Epidermolysis Bullosa Simplex, restoring functional intermediate filament integrity rather than managing downstream symptoms, to shift treatment approaches from palliation toward true disease modification
- Exploring small-molecule strategies designed to rescue skin resilience at the cellular level, preventing blistering and mechanical fragility across EBS subtypes, to improve longterm mobility, wound burden and quality of life
- Building translational and regulatory pathways for first-in-class structural rescue therapies in rare disease, aligning patient need, biomarker development and early clinical strategy, to accelerate meaningful innovation in underserved genetic conditions
12:00 pm Roundtable Discussion: Designing Safer Molecules & Feasible Formulations Earlier to Reduce Off-Target Risk & Improve Development Viability
- Using AI, big data and in silico design to predict receptor selectivity, reducing unexpected off-target effects, to improve confidence before costly clinical investment
- Assessing systemic exposure, metabolite risks and tissuespecific safety liabilities, anticipating unpredictable toxicities, to avoid late-stage failures seen with dermatology standards such as retinoic acid
- Balancing sophisticated formulation design with manufacturability and cost, ensuring preclinical innovation remains commercially viable, to support realistic pipeline progression
TRACK TWO: CLINICAL & COMMERCIAL
Harald Schneider, Chief Executive Officer, Scarletred
Targeting the Root Cause of Disease: Applying Precision Biology to Transform Rare & High-Unmet-Need Dermatology Indications
11:30 am Leveraging mTOR Inhibition to Restore Keratinocyte Homeostasis Across Rare Monogenic Skin Disorders
- Identifying shared pathological mechanisms across monogenic keratin disorders through translational research and patient-derived models
- Evaluating mTOR inhibition as a strategy to restore cellular homeostasis and improve disease outcomes across genetically distinct indications
- Leveraging cross-indication biology to create scalable development pathways in ultra-rare dermatology populations
12:00 pm Advancing Precision Immunology in Vitiligo: Positioning CXCL10 Therapies to Move Beyond Symptom Management
- Evaluating CXCL10 in vitiligo, targeting tissue-resident memory T cells driving depigmentation, to advance more durable and disease-modifying approaches beyond current standard-of-care therapies
- Assessing how CXCL10 compares with JAK inhibitors and phototherapy approaches, addressing limitations around chronic use, safety and relapse, to differentiate next generation vitiligo pipelines in an underserved market
- Understanding growing investor confidence in dermatology innovation, accelerating development in high-unmet-need autoimmune skin disease, to strengthen the commercial outlook for emerging vitiligo therapeutics
12:30 pm Lunch & Networking Break
Finding the Right Biology, Patient & Indication: Improving Early
Development Decisions to Maximize Therapeutic Potential
1:30 pm Unlocking the Endocannabinoid System in Dermatology: Advancing Cannabinoid-Based Therapeutics Across Inflammation, Barrier Dysfunction & Wound Repair
- Examining the biological role of CB1, CB2 and endocannabinoid signaling pathways in skin homeostasis, inflammation and tissue repair, identifying opportunities for therapeutic intervention across dermatological disorders
- Reviewing emerging preclinical and translational evidence supporting cannabinoid-targeted approaches in inflammatory skin disease, wound healing and barrier restoration, to evaluate where meaningful clinical signals may be achieved
- Leveraging dermatology as an efficient proof-of-concept setting for cannabinoid drug development, using accessible tissues and topical delivery strategies to accelerate human translation and de-risk broader development programs
2:00 pm Roundtable Discussion: Identifying the Right Indications to Maximize Signal Detection & Accelerate Development Success
- Pinpointing optimal indications for early assets, increasing signal detection likelihood, to accelerate proof-of-concept
- Aligning indication selection with biology, improving relevance, to enhance success rates
- Prioritizing high-impact indications, maximizing ROI, to drive pipeline efficiency
Optimizing Dermatology Trial Design to Reduce Variability,
Accelerate Readouts & Improve Development Decisions
1:30 pm Using Skin Biomarkers to Address Placebo Response & Endpoint Variability to Improve Signal Detection in AD, HS & Psoriasis Trials
- Understanding rising placebo responses across EASI, IGA and HiSCR-based assessments, reducing interpretive noise, to improve confidence in whether an active therapy is truly effective or underpowered by endpoint variability
- Integrating objective measures such as tape stripping, blood biomarkers, imaging and AI-enabled lesion assessment, capturing earlier biological activity and target engagement, to strengthen early efficacy readouts and support go/no-go decision-making
- Designing trials around disease heterogeneity and patient fluctuation patterns, distinguishing chronic from rapid-cycling disease activity, to reduce placebo interference, improve endpoint timing and increase the likelihood of demonstrating meaningful treatment benefit
2:00 pm Standardizing Global Clinical Trial Conduct to Reduce Operational Variability & Improve Cross-Regional Data Reliability
- Addressing inconsistencies in investigator assessment, adverse event reporting and site conduct across global trial regions, improving operational standardization, to strengthen confidence in safety and efficacy comparisons across multinational studies
- Enhancing site training, oversight and endpoint execution in inflammatory disease trials, reducing investigator-dependent variability and reporting bias, to improve reproducibility across expanding global trial networks
- Balancing increasingly complex biomarker and mechanistic data collection with site and patient burden, streamlining operational workflows and sample logistics, to maintain scalable, executable and regulator-ready study designs
Strengthening Investment, Differentiation & Commercial Positioning to Compete in the Next Era of Dermatology Innovation
2:30 pm Afternoon Break & Refreshments
3:00 pm Improving Evidence Generation to Strengthen Investment Cases & Accelerate Development
- Building robust evidence packages and aligning with investor expectations to secure funding
- Addressing early-stage uncertainties, reducing perceived risk, to unlock investment
- Aligning data with commercial outcomes, strengthening positioning, to drive pipeline progression
- Evolution of endpoints
3:30 pm Establishing New Market Entrants to Compete Effectively & Drive Adoption
- Developing strategies for market entry, reducing launch barriers, to accelerate uptake
- Differentiating products in competitive landscapes, enhancing visibility, to win market share
- Overcoming adoption challenges, aligning with stakeholder needs, to drive commercial success
4:00 pm Why Some Dermatology Programs Become Billion-Dollar Franchises While Others Disappear
4:30 pm Investor Panel: Where Is Dermatology Investment Heading Beyond the Dupixent Era?
- Assessing which indications offer the greatest unmet need and commercial opportunity, guiding portfolio prioritisation, to maximize long-term value creation
- Debating whether the next wave of investment will favour multispecifics, degraders, microbiome therapeutics, AI-designed biologics or engineered-cell approaches, clarifying emerging platform trends, to understand where capital is flowing
- Understanding how investors evaluate differentiation across efficacy, safety, dosing and translational confidence, aligning development strategy with market expectations, to build fundable and partnerable dermatology assets